Telix Pharmaceuticals (ASX:TLX) Clears FDA Trial Step, Does It Look Fairly Valued?

Simply Wall St.

Jul 03

Telix Pharmaceuticals (ASX:TLX) is back in focus after a Type B meeting with the U.S. Food and Drug Administration confirmed that safety data from its ProstACT Global Phase 3 trial supports moving ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2648410658"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2648410658\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2648410658?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-07-03 09:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2648410658","market":"hk","top_or_hot":-1,"title":"Telix Pharmaceuticals (ASX:TLX) Clears FDA Trial Step, Does It Look Fairly Valued?","media":"Simply Wall St.","content":"<div>\n<p>Telix Pharmaceuticals (ASX:TLX) is back in focus after a Type B meeting with the U.S. Food and Drug Administration confirmed that safety data from its ProstACT Global Phase 3 trial supports moving ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/telix-pharmaceuticals-asxtlx-clears-fda-trial-step-does-it-l\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Telix Pharmaceuticals (ASX:TLX) Clears FDA Trial Step, Does It Look Fairly Valued?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTelix Pharmaceuticals (ASX:TLX) Clears FDA Trial Step, Does It Look Fairly Valued?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-03 09:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/telix-pharmaceuticals-asxtlx-clears-fda-trial-step-does-it-l><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Telix Pharmaceuticals (ASX:TLX) is back in focus after a Type B meeting with the U.S. Food and Drug Administration confirmed that safety data from its ProstACT Global Phase 3 trial supports moving ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/telix-pharmaceuticals-asxtlx-clears-fda-trial-step-does-it-l\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/telix-pharmaceuticals-asxtlx-clears-fda-trial-step-does-it-l","article_id":"2648410658","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/telix-pharmaceuticals-asxtlx-clears-fda-trial-step-does-it-l","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2648410658","pubTimestamp":1783042878,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Telix Pharmaceuticals (ASX:TLX) is back in focus after a Type B meeting with the U.S. Food and Drug Administration confirmed that safety data from its ProstACT Global Phase 3 trial supports moving TLX591-Tx into Part 2.\nSee our latest analysis for Telix Pharmaceuticals.\nAlongside the FDA update, Telix Pharmaceuticals has drawn fresh attention after a strong 30-day share price return of 36.03% and year to date share price return of 51.23%. However, the 1-year total shareholder return declined...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4585":"ETF&股票定投概念","LABU":"三倍做多标普生物-Direxion","BK4139":"生物科技","BK7067":"生物科技","TLX.AU":"TELIX PHARMACEUTICALS LTD","TLX":"Telix Pharmaceuticals Ltd. (Uplisting)"},"translate_title":"Telix Pharmaceuticals(ASX：TLX)通过FDA试验步骤，其估值是否合理？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TLX.AU":1,"TLX":1.5,"LABU":1.5},"content_text":"Telix Pharmaceuticals (ASX:TLX) is back in focus after a Type B meeting with the U.S. Food and Drug Administration confirmed that safety data from its ProstACT Global Phase 3 trial supports moving TLX591-Tx into Part 2. See our latest analysis for Telix Pharmaceuticals. Alongside the FDA update, Telix Pharmaceuticals has drawn fresh attention after a strong 30-day share price return of 36.03% and year to date share price return of 51.23%. However, the 1-year total shareholder return declined 28.27%, suggesting near term momentum has improved while longer term holders have had a mixed experience. If Telix’s recent strength in radiopharmaceuticals has you looking wider across the sector, this is a good moment to scan for other precision oncology and healthcare AI opportunities with the 9 healthcare AI stocks With Telix Pharmaceuticals now trading at A$17.18 and sitting at what some analysts view as a discount to both price targets and intrinsic value, is the recent rally leaving more on the table, or is the market already pricing in potential future developments? AdvertisementMost Popular Narrative: 4.6% Undervalued Telix Pharmaceuticals last closed at A$17.18, compared with a narrative fair value of A$18.00. This points to a modest discount rather than an aggressive mispricing.  TLX is a genuine high-conviction, high-risk setup. The infrastructure is being built, the commercial footprint is evident, the pipeline is real, but there are many heavy-weighting factors that could impact their 12-month outlook. Although you are paying for a lot of things going right simultaneously, the market has already repriced some of that optimism out with the stock sitting at $9.87...  Read the complete narrative. If you want to see what sits behind that A$18.00 fair value for Telix Pharmaceuticals, look at how the narrative blends revenue ambitions, margin progression and future earnings multiples into one tight valuation story. Result: Fair Value of A$18.00 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, Telix Pharmaceuticals still faces live risks, including the SEC subpoena on therapeutic disclosures and pressure on Illuccix and Gozellix margins if PSMA imaging competition intensifies. Find out about the key risks to this Telix Pharmaceuticals narrative. Next Steps With sentiment on Telix Pharmaceuticals clearly mixed, this is a useful moment to press pause, review the numbers yourself and decide how comfortable you are with the current risk reward trade off. To see what investors are optimistic about right now, start with the 3 key rewards. Looking for more investment ideas beyond Telix Pharmaceuticals? If Telix Pharmaceuticals has sharpened your interest, do not stop here. Broaden your watchlist with other focused ideas that could inform your overall portfolio decisions.  Spot potential mispricings early by scanning the 9 high quality undervalued stocks before other investors catch on. Strengthen your income stream by reviewing companies in the 5 dividend fortresses that offer higher yields with clear, transparent profiles. Protect your downside by filtering for sturdier businesses through the 9 resilient stocks with low risk scores built around resilience scores and fundamentals.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Telix Pharmaceuticals might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}